| Role |
Name |
Disclosure |
Details |
| Author | Daniel Schneider, MD, Staff Physician, Department of Psychiatry and Neurology, University of Massachusetts | Nothing to disclose | Details | | Coauthor | Paula D Ravin, MD, Associate Professor of Clinical Neurology, University of Massachusetts Memorial Health Care | Nothing to disclose | Details | | Medical Editor | Alan D Schmetzer, MD, Professor and Vice-Chair for Education, Department of Psychiatry, Director of Residency Training, Indiana University School of Medicine | Nothing to disclose | Details | | Pharmacy Editor | Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine | Nothing to disclose | Details | | Managing Editor | Iqbal Ahmed, MD, Program Director, General and Geriatric Psychiatry Residency Programs, Department of Psychiatry, Vice Chair for Education, Professor, John A Burns School of Medicine, University of Hawaii | Nothing to disclose | Details | | CME Editor | Harold H Harsch, MD, Program Director of Geropsychiatry, Department of Geriatrics/Gerontology, Associate Professor, Department of Psychiatry, Assistant Professor, Department of Medicine, Froedtert Hospital, Medical College of Wisconsin | lilly BMS Forest Labs AstraZeneca Pfizer Northstar Novartis | Details | | Chief Editor | Stephen Soreff, MD, President of Education Initiatives, Nottingham, NH; Faculty, Metropolitan College of Boston University, Boston, MA | Nothing to disclose | Details |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Paula D Ravin, Coauthor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Alan D Schmetzer, Medical Editor |
The contributor discloses no conflict of interest. |
Contributor Disclosure
Contributor:
|
Contributor Disclosure: |
| Iqbal Ahmed, Managing Editor |
The contributor discloses no conflict of interest. |
|